U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H10N4O2S
Molecular Weight 214.245
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFAGUANIDINE

SMILES

NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1

InChI

InChIKey=BRBKOPJOKNSWSG-UHFFFAOYSA-N
InChI=1S/C7H10N4O2S/c8-5-1-3-6(4-2-5)14(12,13)11-7(9)10/h1-4H,8H2,(H4,9,10,11)

HIDE SMILES / InChI
Molecular Formula C7H10N4O2S
Molecular Weight 214.245
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://jama.jamanetwork.com/article.aspx?articleid=254816 https://www.mpbio.com/product.php?pid=02102984&country=195

Sulfaguanidine is used to treat the gastrointestinal infections particularly bacillary dysentery. Sulfaguanidine is a sulfonamide antibiotic that blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase in bacteria. Sulfonamides are active against Gram positive bacteria and Gram negative bacteria.

Approval Year

1941
157
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Phase III
665
Unknown

Approved Use

Unknown
Curative
Approved
8583
ENTEROPATHYL

Approved Use

Acute or chronic diarrhea caused by sulfaguanidine-sensitive organisms.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.41 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3820055/
2.5 mg/kg single, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAGUANIDINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.04 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3820055/
2.5 mg/kg single, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAGUANIDINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3820055/
2.5 mg/kg single, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAGUANIDINE plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
4 g 6 times / day multiple, oral
Dose: 4 g, 6 times / day
Route: oral
Route: multiple
Dose: 4 g, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20248057/
unhealthy, 32
Health Status: unhealthy
Age Group: 32
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/20248057/
Other AEs: Anuria...
Other AEs:
Anuria
Sources:
https://pubmed.ncbi.nlm.nih.gov/20248057/
0.05 g/kg 6 times / day multiple, oral
Dose: 0.05 g/kg, 6 times / day
Route: oral
Route: multiple
Dose: 0.05 g/kg, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache
Nausea
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
AEs

AEs

AESignificanceDosePopulation
Anuria
4 g 6 times / day multiple, oral
Dose: 4 g, 6 times / day
Route: oral
Route: multiple
Dose: 4 g, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/20248057/
unhealthy, 32
Health Status: unhealthy
Age Group: 32
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/20248057/
Headache Disc. AE
0.05 g/kg 6 times / day multiple, oral
Dose: 0.05 g/kg, 6 times / day
Route: oral
Route: multiple
Dose: 0.05 g/kg, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
Nausea Disc. AE
0.05 g/kg 6 times / day multiple, oral
Dose: 0.05 g/kg, 6 times / day
Route: oral
Route: multiple
Dose: 0.05 g/kg, 6 times / day
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: F
Sources:
https://jamanetwork.com/journals/jama/article-abstract/257467
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:94621
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:94621
ChemicalBook
CB7152799
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7152799
eMolecules
474314
https://www.emolecules.com/cgi-bin/more?vid=474314
MolPort
MolPort-000-900-613
https://www.molport.com/shop/molecule-link/MolPort-000-900-613
MolPort
MolPort-002-939-432
https://www.molport.com/shop/molecule-link/MolPort-002-939-432
Selleck Chemicals
sulfaguanidine
http://www.selleckchem.com/products/sulfaguanidine.html
ZINC
ZINC000003873927
http://zinc15.docking.org/substances/ZINC000003873927
PubMed

PubMed

TitleDatePubMed
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996-12
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.
1996-04
Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.
1995-08
In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.
1994-10
Patents

Patents

07105529
1
20020045223
1
JP2003515526A
470

Sample Use Guides

In Vivo Use Guide
0.08 mg/kg per day; 7-14 days (daily dose: 2-3 mg)
Route of Administration: Oral
In Vitro Use Guide
Sulfaguanidine at dose of 2500 ppm proved to be most toxic against A. corymbifera causing 56.39 percent inhibition in the mycelial growth, while the same dose could not be found much effective against other test fungi.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:54:58 GMT 2025
Edited
by admin
on Mon Mar 31 17:54:58 GMT 2025
Record UNII
15XQ8043FN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFAGUANIDINE
EP   INN   MART.   MI   WHO-DD  
INN  
Official Name English
NSC-14041
Preferred Name English
SULFAGUANIDINE [EP IMPURITY]
Common Name English
SULFAGUANIDINE [EP MONOGRAPH]
Common Name English
Sulfaguanidine [WHO-DD]
Common Name English
sulfaguanidine [INN]
Common Name English
SULFAGUANIDINE [MART.]
Common Name English
SULFADIAZINE IMPURITY C [EP IMPURITY]
Common Name English
SULFADIMIDINE IMPURITY C [EP IMPURITY]
Common Name English
SULFAGUANIDINE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
WHO-ATC A07AB03
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
WHO-VATC QA07AB03
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID1023609
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
MESH
D013414
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
CAS
57-67-0
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
PUBCHEM
5324
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
WIKIPEDIA
SULFAGUANIDINE
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
CHEBI
94621
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
NCI_THESAURUS
C76977
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
DRUG BANK
DB13726
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
ChEMBL
CHEMBL338802
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-345-9
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
NSC
14041
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
DRUG CENTRAL
2505
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
EVMPD
SUB10703MIG
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
INN
423
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
RXCUI
10174
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m10310
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY Merck Index
SMS_ID
100000083248
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
FDA UNII
15XQ8043FN
Created by admin on Mon Mar 31 17:54:58 GMT 2025 , Edited by admin on Mon Mar 31 17:54:58 GMT 2025
PRIMARY
Related Record Type Details
Structure of SULFAMETHAZINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of SILVER SULFADIAZINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of SULFADIAZINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of SULFAGUANIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966